Aprogen Medicines Inc. (KRX:007460)
South Korea flag South Korea · Delayed Price · Currency is KRW
2,280.00
-65.00 (-2.77%)
Aug 21, 2026, 3:30 PM KST

Aprogen Medicines Cash Flow Statement

Millions KRW. Fiscal year is Jan - Dec.

Operating Activities

Fiscal Year
TTMFY 2025FY 2024FY 2023FY 2022FY 2021
Period Ending
Mar '26 Dec '25 Dec '24 Dec '23 Dec '22 Dec '21
Net Income
-73,268-70,202-58,079-55,619-98,657-93,920
Depreciation & Amortization
23,29023,59724,30529,07128,39225,262
Loss (Gain) From Sale of Assets
2,7912,786201.14-30.3457.39-
Asset Writedown & Restructuring Costs
798.31739.83801.872,2719,162223.61
Loss (Gain) From Sale of Investments
-2,600-1,749-303-341.932,7441,228
Loss (Gain) on Equity Investments
39,92839,375--1,4899,543
Stock-Based Compensation
729.411,1521,7181,613707.672,445
Provision & Write-off of Bad Debts
46.23384.751,573-8.5-5,001-
Other Operating Activities
-53,397-56,850-18,663-19,249-35,587-17,926
Change in Accounts Receivable
834.983,558-207.691,7493,395778.84
Change in Inventory
-11,695-4,0301,270-5,024-17,526-8,367
Change in Accounts Payable
8,103-2,683-4,369-3,491-1,8523,378
Change in Income Taxes
-222.7-222.7-217.8935.78770.88
Change in Other Net Operating Assets
-1,69831,4876,761-9,315-2,151-8,155
Operating Cash Flow
-66,361-32,657-44,992-58,156-113,491-84,740
Operating Cash Flow Growth
------

Investing Activities

Fiscal Year
TTMFY 2025FY 2024FY 2023FY 2022FY 2021
Period Ending
Mar '26 Dec '25 Dec '24 Dec '23 Dec '22 Dec '21
Capital Expenditures
-5,820-8,994-12,671-25,514-19,610-34,392
Sale of Property, Plant & Equipment
344.8373.3483.042,273131.6540.06
Cash Acquisitions
-5,080-5,080-127.87-39,940-
Divestitures
58,12158,122300-29,285-
Sale (Purchase) of Intangibles
-12,239-11,931-10,473-29,371-5,209-474.06
Investment in Securities
15,703-59,583-9,486965.6827,26818,390
Other Investing Activities
-34,515-36,702-8,1308,193-1,690-924.3
Investing Cash Flow
16,516-63,795-40,504-43,45270,172-12,790

Financing Activities

Fiscal Year
TTMFY 2025FY 2024FY 2023FY 2022FY 2021
Period Ending
Mar '26 Dec '25 Dec '24 Dec '23 Dec '22 Dec '21
Short-Term Debt Issued
-37,50011,05014,61096,500134,190
Long-Term Debt Issued
-158,83536,35096,546-30,845
Total Debt Issued
114,339196,33547,400111,15696,500165,035
Short-Term Debt Repaid
--12,300-11,350-40,110-7,500-27,000
Long-Term Debt Repaid
--82,560-12,967-8,481-1,873-30,220
Total Debt Repaid
-72,990-94,860-24,317-48,591-9,373-57,220
Net Debt Issued (Repaid)
41,349101,47523,08362,56587,127107,815
Issuance of Common Stock
--0.765,51530.972,583
Repurchase of Common Stock
---0.1--15,791-
Dividends Paid
-0.08-0.08----
Other Financing Activities
1,4181,46763,53726,216-561.9-0
Financing Cash Flow
42,767102,94186,62194,29670,804110,398

Net Cash Flow

Fiscal Year
TTMFY 2025FY 2024FY 2023FY 2022FY 2021
Period Ending
Mar '26 Dec '25 Dec '24 Dec '23 Dec '22 Dec '21
Foreign Exchange Rate Adjustments
1,9941,497352.04-72.93-309.074.05
Miscellaneous Cash Flow Adjustments
-0-----
Net Cash Flow
-5,0847,9871,477-7,38527,17612,872

Free Cash Flow

Fiscal Year
TTMFY 2025FY 2024FY 2023FY 2022FY 2021
Period Ending
Mar '26 Dec '25 Dec '24 Dec '23 Dec '22 Dec '21
Free Cash Flow
-72,181-41,651-57,662-83,669-133,101-119,132
Free Cash Flow Growth
------
Free Cash Flow Margin
-56.59%-35.30%-38.41%-55.57%-169.88%-453.05%
Free Cash Flow Per Share
-3581.95-2100.37-3344.16-5314.11-9864.93-10307.07
Levered Free Cash Flow
-152,660-91,444-41,649-21,656-145,21326,095
Unlevered Free Cash Flow
-148,746-88,467-41,019-21,261-139,02239,697

Additional Metrics

Fiscal Year
TTMFY 2025FY 2024FY 2023FY 2022FY 2021
Period Ending
Mar '26 Dec '25 Dec '24 Dec '23 Dec '22 Dec '21
Cash Interest Paid
2,7712,821630.7242.7610,99211,339
Cash Income Tax Paid
3,2182,921220.01-2,1283,291398.92
Change in Working Capital
-4,67828,1103,454-15,862-17,199-11,594